2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases

  • Bioorg Med Chem Lett. 2007 Jun 15;17(12):3349-53. doi: 10.1016/j.bmcl.2007.03.102.
Mark E Schnute  1 ,  David J Anderson ,  Roger J Brideau ,  Fred L Ciske ,  Sarah A Collier ,  Michele M Cudahy ,  MariJean Eggen ,  Michael J Genin ,  Todd A Hopkins ,  Thomas M Judge ,  Euibong J Kim ,  Mary L Knechtel ,  Sajiv K Nair ,  James A Nieman ,  Nancee L Oien ,  Allen Scott ,  Steven P Tanis ,  Valerie A Vaillancourt ,  Michael W Wathen ,  Janet L Wieber
Affiliations
  • 1. Global Research and Development, Pfizer Inc., 700 Chesterfield Parkway West, St. Louis, MO 63017, USA. [email protected]
PMID: 17434304 DOI: 10.1016/j.bmcl.2007.03.102
Abstract

A novel series of 2-aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides have been identified as potent antivirals against human herpesviruses. These compounds demonstrate broad-spectrum inhibition of the herpesvirus polymerases HCMV, HSV-1, EBV, and VZV with high specificity compared to human DNA polymerases.